-
Sanofi's targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
On September 27th, Sanofi announced that Dapitumab Injection has been approved by the China National Medical Products Administration for use in adult patients with chronic obstructive pulmonary disea ... -
The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
Southern Finance and Economics, September 27th - Sanofi announced that Dabitou& reg; Dupilumab injection has been approved by the National Medical Products Administration (NMPA) of China for use in a ... -
Sanofi's star drug was approved on the same day in China and the United States, marking the first treatment plan for this common lung disease
On Friday (September 27th) local time, Sanofi and Regeneron Pharmaceuticals both announced on their official websites that their heavyweight drug "Dabitol" was approved in China and the United States ...